Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07835698

The Validation of ICBT Clinical Trial: Disease Stress Adjustment in Breast Cancer Patients

Breast cancer and its treatment can cause ongoing emotional distress, including anxiety, depressive symptoms, stress-related reactions, and difficulties adjusting to life after treatment. This study evaluates an 8-week Internet-based cognitive behavioral therapy (ICBT) program designed to support psychological adjustment and improve quality of life among adults with stage I-III breast cancer who have completed primary cancer treatment.

Approximately 100 participants will be randomly assigned to either an ICBT group or a control group. Participants in the ICBT group will receive treatment as usual together with the 8-week online program, while participants in the control group will receive treatment as usual alone during the main study period. The study will compare changes in anxiety, depressive symptoms, post-traumatic stress symptoms, and quality of life between the two groups.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Breast cancer survivors may continue to experience psychological distress after completing primary cancer treatment. Barriers such as limited access to psychological services, time constraints, and concerns about stigma may prevent patients from receiving timely mental health support. Internet-based cognitive behavioral therapy may provide a flexible and accessible approach to supporting psychological adjustment among this population.

This randomized, parallel-group study aims to evaluate the effectiveness of an 8-week culturally adapted Internet-based cognitive behavioral therapy program for adults with stage I-III breast cancer who have completed primary treatment. The program, titled "Healthy Steps: Women's Mental Well-Being," integrates cognitive behavioral therapy principles, psycho-oncology experience, and digital intervention technology.

Approximately 100 participants will be randomly assigned to one of two groups. Participants in the intervention group will continue to receive treatment as usual and will additionally complete the 8-week ICBT program through a mobile application developed by the National Health Research Institutes. The program includes content and exercises related to self-compassion, cognitive restructuring, emotional regulation, and stress management. The study system will be used to record learning progress, questionnaire completion, and program use.

Participants in the control group will receive treatment as usual without additional ICBT during the main comparative study period. After completing the study assessments, control-group participants may request access to the ICBT program.

Assessments will be conducted at baseline, week 5, week 9, and 3 months after completion of the intervention period. The primary analyses will compare changes in anxiety symptoms, depressive symptoms, post-traumatic stress symptoms, and quality of life between the intervention and control groups. Exploratory analyses will examine the relationships between attachment orientation and changes in psychological outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-65 years.
  • Diagnosis of stage I-III breast cancer.
  • Completion of primary breast cancer treatment, including surgery, chemotherapy, radiation therapy, and/or targeted therapy. Participants currently receiving endocrine therapy are eligible.
  • Ability to read and write Chinese and to use a mobile application and the Internet.
  • Access to an Internet-enabled device and ability to independently participate in the online intervention.
  • Willingness to complete the online intervention modules and study assessment questionnaires.

Exclusion criteria

  • Diagnosis of stage IV breast cancer.
  • Concurrent diagnosis of another type of cancer.
  • Currently receiving surgery, chemotherapy, radiation therapy, or targeted therapy for breast cancer.
  • Diagnosis of a psychiatric disorder within the past 6 months, including major depressive disorder, generalized anxiety disorder, or schizophrenia.
  • No current psychiatric diagnosis but a Patient Health Questionnaire-9 (PHQ-9) score greater than 20 at screening.
  • Current suicidal intent or a history of actual self-harm behavior.
  • Currently receiving another form of psychotherapy or having recently received cognitive behavioral therapy.
  • Inability to independently use the online intervention application because of insufficient Chinese literacy, Internet proficiency, or access to an Internet-enabled device.

Treatment and study plan

Internet-Based Cognitive Behavioral Therapy Program for Breast Cancer Survivors

Behavioral

An 8-week Internet-based cognitive behavioral therapy program delivered through a mobile application. The program includes psychoeducational content and exercises related to self-compassion, cognitive restructuring, emotional regulation, stress management, relaxation, mindfulness, and coping with cancer-related concerns.

Other names: ICBT, Healthy Steps: Women's Mental Well-Being

Treatment as usual (TAU)

Other

Participants will continue to receive routine clinical care provided by their treating health care professionals. No additional Internet-based cognitive behavioral therapy will be provided during the main comparative study period.

Other names: TAU

Primary outcomes

  1. Change in Psychological Distress as Assessed by the Depression, Anxiety and Stress Scale-21

    Time frame: Baseline to Week 9

    Psychological distress will be assessed using the 21-item Depression, Anxiety and Stress Scale (DASS-21), which includes depression, anxiety, and stress subscales. Each item is rated on a 4-point scale from 0 to 3. Higher scores indicate greater levels of psychological distress. Changes in scores will be compared between the ICBT and TAU groups.

Secondary outcomes

  1. Change in Depressive Symptoms as Assessed by the Patient Health Questionnaire-9

    Time frame: Baseline, Week 5, Week 9, and 3 months after the intervention period

    Depressive symptoms will be assessed using the 9-item Patient Health Questionnaire (PHQ-9). The total score ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms. Changes in scores will be compared between the ICBT and TAU groups.

  2. Change in Post-Traumatic Stress Symptoms as Assessed by the Posttraumatic Diagnostic Scale for DSM-5

    Time frame: Baseline, Week 5, Week 9, and 3 months after the intervention period

    Post-traumatic stress symptoms will be assessed using the Posttraumatic Diagnostic Scale for DSM-5 (PDS-5). The scale assesses the severity of post-traumatic stress symptoms and associated distress and functional impairment. Higher scores indicate greater severity of post-traumatic stress symptoms.

  3. Change in Life Satisfaction as Assessed by the Satisfaction With Life Scale

    Time frame: Baseline, Week 5, Week 9, and 3 months after the intervention period

    Life satisfaction will be assessed using the 5-item Satisfaction With Life Scale (SWLS). The total score ranges from 5 to 35, with higher scores indicating greater satisfaction with life.

  4. Change in Insomnia Severity as Assessed by the Insomnia Severity Index

    Time frame: Baseline, Week 5, Week 9, and 3 months after the intervention period

    Insomnia severity will be assessed using the 7-item Insomnia Severity Index (ISI). The total score ranges from 0 to 28, with higher scores indicating greater insomnia severity.

  5. Change in Fatigue as Assessed by the Brief Fatigue Inventory

    Time frame: Baseline, Week 5, Week 9, and 3 months after the intervention period

    Fatigue will be assessed using the 9-item Brief Fatigue Inventory (BFI), which evaluates fatigue severity and its interference with daily functioning during the previous 24 hours. Items are rated from 0 to 10, with higher scores indicating greater fatigue severity or interference.

  6. Change in Fear of Cancer Recurrence as Assessed by the 7-Item Fear of Cancer Recurrence Scale

    Time frame: Baseline, Week 5, Week 9, and 3 months after the intervention period

    Fear of cancer recurrence will be assessed using the 7-item Fear of Cancer Recurrence Scale (FCR7). Each item is rated from 0 to 4, and the total score ranges from 0 to 28. Higher scores indicate greater fear of cancer recurrence.

  7. Change in Self-Compassion as Assessed by the Self-Compassion Scale

    Time frame: Baseline, Week 5, Week 9, and 3 months after the intervention period

    Self-compassion will be assessed using the Self-Compassion Scale (SCS). Higher scores indicate greater self-compassion.

  8. Change in Post-Traumatic Growth as Assessed by the Posttraumatic Growth Inventory-X

    Time frame: Baseline, Week 5, Week 9, and 3 months after the intervention period

    Post-traumatic growth will be assessed using the 25-item Posttraumatic Growth Inventory-X (PTGI-X). Items are rated from 0 to 5, resulting in a total score ranging from 0 to 125. Higher scores indicate greater perceived positive change following a traumatic experience.

Sponsors and collaborators

Lead sponsor

National Health Research Institutes, Taiwan

Other

Registry information

Acronym: ICBT-TW-2

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 23, 2026
Registry last updated
Sep 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.